Specifications of Melanotan I Acetate

Afamelanotide is the International Nonproprietary Name for the molecule [Nle4, D-Phe7]α-MSH [2] initially researched and developed as melanotan-1 and later, CUV1647 [by Clinuvel]. A marketing trade name for one brand of afamelanotide was recently approved by the European Medicines Agency (EMA) Name Review Group (NRG) and the Agency's Committee for Human Medicinal Products (CHMP) as Scenesse (pronounced "sen-esse"). On May 5, 2010 the Italian Medicines Agency (AIFA - Agenzia Italiana del Farmaco) became the first governmental health organization ever (even before the drug received approval in Europe) to authorize afamelanotide as a medicine for therapeutic treatment of Italian citizens to reduce painful photosensitivity stemming from the orphan disease of a "grain of rice" sized bioabsorbable subcutaneous implant as a potential therapeutic photoprotection inducing agent for a series of light related skin indications.

Item Name: MelanotanⅠ Acetate
Molecular Formula: C78H111N21O19
CAS No.: 75921-69-6
Properties of Melanotan I Acetate:
density  1.43
storage temp.  -20°C
solubility  H2O: 5 mg/mL, soluble
form  solid
Specifications of Melanotan I Acetate:
Purity (HPLC)                                        98%min.
Appearance                                        White powder
Single Impurity (HPLC)                      1.0%max
Amino Acid Composition               ±10% of theoretical
Peptide Content (N%)                         ≥80.0%
Water Content (Karl Fischer)             ≤5.0%
Acetate Content (HPIC)                       ≤10.0%
MS (ESI)                                              Consistent
Mass Balance                                     95.0~105.0%
Read More: Melanotan I Acetate for sale